Propranolol hydrochloride propranolol

Treatment regimen was chosen according to the literature2 (link) to block β-adrenergic signalling pathways and not to perform a pre-clinical study on the effect of β-blockers in stroke. (S)-(−)-Propranolol hydrochloride (propranolol; Sigma Aldrich) (30 mg kg⁻¹) was administered by i.p injection immediately before and 4 h after MCAO. An equivalent volume of PBS was administered in vehicle-treated animals. Animals were recovered for 2 d after MCAO and tissues collected as described above.

(±) Propranolol hydrochloride (propranolol) (Sigma) was dissolved in room temperature drinking water at 0.5 g/L and offered to mice ad libitum, starting on the day of cancer cell inoculation. Water bottles for all mice were changed every 3–4 days. In checkpoint inhibitor treated groups, mice were treated intraperitoneally (i.p.) three times a week, starting 1 day after cancer cell inoculation, with anti-PDL1 mAb (200 μg/mouse; clone 10 F.9G2, BioXcell), anti-CTLA4 mAb (200 μg/mouse; clone 9D9, BioXcell), anti-PD1 mAb (200 μg/mouse; clone RMP1-14, BioXcell), alone or in combinations until endpoint or one week after tumor clearance. Control mice were treated with PBS following the same treatment scheme.